Drug General Information (ID: DDI8XUO3G5)
  Drug Name Ceftriaxone Drug Info Calcium gluconate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antibiotics Minerals And Electrolytes
  Structure

 Mechanism of Ceftriaxone-Calcium gluconate Interaction (Severity Level: Major)
     Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph
      Drug Name Ceftriaxone Calcium gluconate
      Mechanism Ceftriaxone Increase the risk of calcium salt precipitation in combination with ceftriaxone
      Key Mechanism Factor 1
Factor Name Adverse reactions
Factor Description An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly.
      Mechanism Description
  • Increased risk of adverse reactions by the combination of Ceftriaxone and Calcium gluconate 

Recommended Action
      Management Ceftriaxone must not be mixed or administered simultaneously with intravenous calcium-containing solutions (e.g., Ringer's or Hartmann's solution parenteral nutrition containing calcium) via a Y-site in any patient regardless of age. Concomitant use of ceftriaxone and intravenous calcium-containing products (or within 48 hours of each other) is considered contraindicated in neonates 28 days of age or younger, even when administered via different infusion lines at different sites. Ceftriaxone should not be used in neonates if they are receiving, or are expected to receive, calcium-containing intravenous products. In patients older than 28 days, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. No data or recommendations are available for concomitant use of intravenous ceftriaxone and oral calcium-containing products or intramuscular ceftriaxone and calcium-containing products (IV or oral).

References
1 Product Information. Rocephin (ceftriaxone). Roche Laboratories, Nutley, NJ.
2 Bradley JS, Wassel RT, Lee L, Nambiar S "Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events." Pediatrics (2009):. [PMID: 19289450]
3 CDER. Center for Drug Evaluation and Research. FDA. U.S. Food and Drug Admninistration "Information for health care professionals: ceftriaxone (marketed as Rocephin and its generics)."